The use of glucocorticoids in rheumatoid arthritis - no 'rational' approach yet

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Desai, Sonali P ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 7; PREDNISONE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT;

BONE DENSITY; BONE METABOLISM; EDITORIAL; GENETIC POLYMORPHISM; HUMAN; IMMUNE SYSTEM; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; RHEUMATOID ARTHRITIS; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; NOTE; TIME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; TIME FACTORS;

EID: 79960333907     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3035     Document Type: Editorial

References (11)

1. Ibanez M, Ortiz AM, Castrejon I, Garcia-Vadillo A, Carvajal I, Castaneda S, Gonzalez-Alvaro I. A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 12:R50. 2888199, 20331862, 10.1186/ar2961.
2. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. 1858257, 9546355.
3. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210. 2688223, 19232069, 10.1186/ar2571.
4. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328. 10.1007/s00198-007-0394-0, 17566815.
5. Maurice MM, Nakamura H, van der Voort EA, van Vliet AI, Staal FJ, Tak PP, Breedveld FC, Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318. 10.1016/S0140-6736(97)01300-7, 9251634.
6. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007, CD006356.
7. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005, 20:464-470. 10.1359/JBMR.041125, 15746991.
8. Engvall IL, Svensson B, Tengstrand B, Brismar K, Hafstrom I. Impact of lowdose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008, 10:R128. 2656227, 18986531, 10.1186/ar2542.
9. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005, 165:1293-1297. 15956010, 10.1001/archinte.165.11.1293.
10. Sliwinska-Stanczyk P, Pazdur J, Ziolkowska M, Jaworski J, Kaminska-Tchorzewska E, Lacki JK. The effect of methylprednisolone on proliferation of PBMCs obtained from steroid-sensitive and steroid-resistant rheumatoid arthritis patients. Scand J Rheumatol 2007, 36:167-171. 10.1080/03009740601154111, 17657668.
11. Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009, 1179:179-198. 10.1111/j.1749-6632.2009.05013.x, 19906240.